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INTRODUCTION
The War on Cancer: An Update from
the New Haven Theater of Operations
Daniel DiMaio, MD, PhD
Yale University School of Medicine, New Haven, Connecticut
In the early 1970s, the National Cancer
Institute declared war on cancer.As in any
military campaign, the first requirement for
success is the accumulation of reliable in-
telligence about the enemy. The first few
decades of this war were spent generating
the tools to gather this intelligence: restric-
tion endonucleases to analyze and restruc-
ture DNA and monoclonal antibodies to
diagnose and treat cancer; recombinant
DNA technology and the birth of the
biotechnology industry; DNA sequencing
techniques and the dawn of the genomics
era; improved methods to analyze tumor
cells; and better animal models of cancer.
Armed with these tools, fundamental ques-
tions could be posed: What actually is can-
cer, what are its hallmarks, what are its
causes, what are its vulnerabilities?The an-
swers so far include the discovery of onco-
genes and tumor suppressor genes, the
elucidation of signaling pathways central to
cancer development, the discovery that
some human cancers are caused by viruses
and bacteria, and the implementation of
vaccination and antibiotic treatment strate-
gies to prevent these cancers. Recent years
also have seen the development of specific
drugs that attack the molecular machinery
of cancer, such as Herceptin for breast can-
cer and Gleevec for some forms of
leukemia and other cancers. Indeed, for the
first time, rates of cancer mortality in the
United States are declining, largely due to
improvements in our ability to diagnose
and treat cancer in its earlier stages.
Despite these successes, cancer re-
mains a formidable problem, and the public
isimpatientthatprogresshasnotbeenmore
rapid. There are several reasons why the
war is not yet won. Cancer is largely a dis-
ease of aging, and the prevention of prema-
ture deaths caused by infectious diseases
has resulted in the survival of more people
into the years of peak cancer susceptibility.
Other demographic factors, including the
obesity epidemic and our inability to elimi-
nate tobacco use, also hinder efforts to con-
trol cancer. The other major barrier to
cancer eradication is its complexity. Cancer
isnotasingledisease,butratheracollection
of many different, albeit related, diseases.
Although molecular studies have revealed
that a relatively small number of biochemi-
calandgeneticpathwaysareresponsiblefor
cancer, the spectrum of cancers is quite di-
verse, depending on the specific cell types
affected and the precise mechanism of car-
cinogenesis.Nevertheless,despitethiscom-
plexity,ahandfulofgeneralprincipleshave
emerged — cancer, even non-hereditary
cancer, has largely a genetic basis; carcino-
genesis is usually a stepwise process entail-
ing the activation of cellular oncogenes and
inactivation oftumorsuppressorgenes.The
genesis of individual tumors can be pin-
pointedwithprecisionfrommolecularchar-
acterization of tumor cells, information thatDiMaio: Introduction 84
in some cases can provide important infor-
mation about prognosis and treatment re-
sponse. The pathways implicated in cancer
often play crucial roles in the life and death
of normal cells, the maintenance of genomic
integrity, and organismal development. The
immune system and other intrinsic defense
mechanisms play a major role in preventing
tumor formation.
We have made great headway in under-
standing cancer and are making the first in-
roads into targeted therapy, but much still
remains to be done.This is an opportune time
foraspecialcancerissueoftheYaleJournalof
Biology and Medicine.This issue contains ar-
ticles, essays, reviews, case reports, and inter-
views that touch upon many important topics
in contemporary cancer research, with a par-
ticular emphasis on work carried out atYale.
A number of important themes are evi-
dent from the papers in this issue. First, to-
gether with focused studies of individual
cancers, there is a need to consider broader
paradigms of carcinogenesis. Two review ar-
ticlesaddressthisissue.Isthestandardmulti-
hit hypothesis of the sequential accumulation
ofmutationsadequatetoexplaincancer,andis
inflammation a common co-factor in cancer
that needs to be explored more thoroughly?
Second, as exemplified by a small series of
casereportsandarticles,carefulstudiesoftu-
mors and patients can yield important infor-
mation. Although much can be learned from
cultured cells and model organisms, great in-
sight also can be gleaned from studies of pa-
tients and patient material. This is especially
true now that better tools are available to an-
alyze and compare tumor and normal tissue.
Suchclinicalstudiesareessentialifcancerbi-
ology is to move beyond elegant mechanistic
understanding to well-designed clinical trials
andsuccessfulpreventivemeasuresandtreat-
ments. Third, studies on rare hereditary can-
cers can elucidate the fundamental causes of
common, sporadic tumors.
Several articles imply that we are more
similartoourcousinslowerontheevolution-
arytreethanwemightliketothink,andgreat
benefit can accrue from studies of organisms
moreamenabletodetailedgeneticstudiesbe-
cause of their rapid generation time and sim-
pler genetic and cellular make-up. Studies of
yeast, roundworms, fruit flies, and mice all
provide new insight into important topics
suchasthedeterminantsofmetastasisandthe
role of non-coding RNAs. Finally, a review
articleandanessayremindusthatvirusesare
important human carcinogens uniquely sus-
ceptible to prevention through public health
measures such as vaccination. In addition,
studiesofviruseshavehistoricallyelucidated
the basic molecular machinery of cell sur-
vival, growth, and cancer development, and
viral-induced cancers may serve as useful
model systems with well-defined targets to
develop innovative treatment approaches.
Interviews with two Yale faculty mem-
bers highlight the human dimension of can-
cer research. Both Haifan Lin and Tian Xu
survived the excesses of the Cultural Revo-
lution in China to establish outstanding re-
search careers in the United States. Dr. Lin,
the head of the new stem cell program at
Yale, discusses the importance of cancer
stem cells, a new concept that may deepen
our understanding of the origins of cancer
and improve our ability to treat it. He also
considers the unique contribution that scien-
tists atYale, working with the support of the
state of Connecticut, can make to studies in
this field. Dr. Xu is pioneering innovative
approaches to manipulate the mouse cell
genome and study metastasis, the deadly
process by which cancer cells spread
throughout the body. He presents his vision
for the future of cancer research and pro-
vides a glimpse of new technology that may
revolutionize studies of cancer biology.
This is an exciting time in cancer re-
search. We have seen many important dis-
coveries, but it is clear much of the
interesting biology that underlies cancer is
still poorly understood. Attempts to trans-
form our knowledge into more effective
methods to prevent and treat cancer are still
in their infancy. This issue of the Yale Jour-
nal of Biology and Medicine highlights
some of the important advances that have
occurred, frames some of the questions that
remain, and provides insight into the ap-
proaches, ideas, and people who will carry
the field forward.